share_log

Compass Therapeutics to Participate in the Piper Sandler 36th Annual Healthcare Conference

Compass Therapeutics to Participate in the Piper Sandler 36th Annual Healthcare Conference

compass therapeutics將參加派傑投資第36屆年度醫療保健大會
GlobeNewswire ·  12/02 21:00

BOSTON, Dec. 02, 2024 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced that the Company will present at the Piper Sandler 36th Annual Healthcare Conference taking place in New York City, NY December 3-5, 2024.

波士頓,2024年12月02日(環球新聞社)- compass therapeutics 公司(納斯達克股票代碼:cmpx)一家專注於腫瘤治療的臨床階段生物製藥公司,正在開發用於治療多種人類疾病的專有抗體療法,今天宣佈公司將參加於2024年12月3-5日在紐約舉行的派傑投資第36屆健康醫療大會。

Presentation details
Date: Wednesday, December 4, 2024
Time: 9:50-10:10 AM EST
Webcast Link:

演講詳情
日期:2024年12月4日星期三
時間:美國東部時間上午9:50-10:10
網絡廣播鏈接:

Virtual/Replay availability: The corporate presentation will be archived for 90 days on Compass' Events page.

虛擬/重播可用性:公司演示將存檔在compass活動頁面上,爲期90天。

About Compass Therapeutics
Compass Therapeutics, Inc. is a clinical-stage oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. Compass's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth. The company pipeline of novel product candidates is designed to target multiple critical biological pathways required for an effective anti-tumor response. These include modulation of the microvasculature via angiogenesis-targeted agents, induction of a potent immune response via activators on effector cells in the tumor microenvironment, and alleviation of immunosuppressive mechanisms used by tumors to evade immune surveillance. Compass plans to advance its product candidates through clinical development as both standalone therapies and in combination with proprietary pipeline antibodies based on supportive clinical and nonclinical data. The company was founded in 2014 and is headquartered in Boston, Massachusetts. For more information, visit the Compass Therapeutics website at .

關於compass therapeutics
Compass Therapeutics是一家臨床階段的生物製藥公司,致力於開發基於專利抗體的治療多種人類疾病的專有治療產品。Compass的科學重點是在血管生成、免疫系統和腫瘤生長之間的關係。該公司的新穎產品候選藥物流水線旨在針對多個關鍵的生物途徑,這些途徑對於有效的抗腫瘤反應非常重要。這些包括通過靶向血管生成的藥物對微血管的調節,通過在腫瘤微環境中的效應細胞上激活劑誘導強效免疫反應,並減輕瘤細胞用來逃避免疫監視的免疫抑制機制。Compass計劃通過臨床發展將其產品候選藥物作爲獨立療法和與基於支持性臨床和非臨床數據的專有流水線抗體組合使用。該公司成立於2014年,總部位於馬薩諸塞州波士頓。有關更多信息,請訪問Compass Therapeutics網站。

Investor Contact
ir@compasstherapeutics.com

投資者聯繫人
ir@compasstherapeutics.com

Media Contact
Anna Gifford, Senior Manager of Communications
media@compasstherapeutics.com
617-500-8099

媒體聯繫
安娜·吉福德,通信-半導體高級經理
media@compasstherapeutics.com
617-500-8099


声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論